At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years
- ✓Primary, newly diagnosed FIGO Stage II-IV epithelial ovarian/fallopian tube/peritoneal cancer
- ✓Low or high grade serous or endometrioid histology
- ✓Debulking surgery performed
- ✕Progressive disease at end of adjuvant treatment
- ✕Women of childbearing potential without sterilization or surgical resection prior to intervention
- ✕Pregnant or lactating women
- ✕Other malignancy within last 5 years with impact on prognosis
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).
In Brief
A Phase 3 clinical trial evaluating Letrozole 2.5mg and Placebo for Ovarian Neoplasm Epithelial and 5 related conditions. Currently recruiting, targeting 540 participants across 53 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo. The study's primary hypothesis is that the treatment with letrozole increases progression free survival in comparison to the maintenance standard treatment (superiority trial).
Study Details
Timeline
Interventions
Aromatase inhibitor
Placebo tablet of Femara